Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

Tesofensine: does it work, is it legal, and what does it cost?

Not a peptide: an oral triple reuptake inhibitor that produced about 10% placebo adjusted weight loss over 24 weeks in a phase 2 RCT. Not FDA approved.

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

Quick answers

Quick answers about Tesofensine
Does it work in people?Evidence: Human RCT evidence

At least one randomized human trial in PubMed. See the evidence

Is it legal?Regulatory: Unscheduled

Not FDA approved and not on FDA's list of substances pharmacies may compound (the 503A bulks list), so a pharmacy has no federal basis to compound it. [3] [4] See legal status

What does it cost?Not available through licensed US channels. Insurance does not cover it. See cost by channel
Side effects?Dry mouth (most common). Nausea, constipation, and hard stools. Insomnia and mood changes. See side effects and interactions
Tested athlete?WADA: WADA prohibited

What is Tesofensine?

Tesofensine is an oral small molecule, not a peptide, that blocks reuptake of serotonin, noradrenaline, and dopamine and was first studied for Parkinson and Alzheimer disease before weight loss was noticed. In a 24 week randomized trial of 203 obese adults, 0.5 mg daily produced 9.2% and 1.0 mg 10.6% placebo adjusted weight loss, with dose related increases in heart rate and blood pressure. It has not been approved by FDA and appears on peptide sellers' lists only because it is marketed alongside them.

Tesofensine is an oral small molecule triple monoamine (serotonin, noradrenaline, dopamine) reuptake inhibitor; not a peptide. It is also known as NS 2330, NS-2330, Tesofensine citrate.

How does it work?

Tesofensine inhibits the presynaptic transporters for serotonin, noradrenaline, and dopamine, raising synaptic levels of all three. The appetite suppression is attributed mainly to noradrenergic and dopaminergic effects on hypothalamic feeding circuits, with a smaller contribution from increased energy expenditure. It has an active metabolite and a long half life of several days.

Key facts
ClusterMetabolic and growth hormone axis
RoutesOral tablet or capsule, once daily
Conditions studiedObesity and chronic weight management; Fat loss and body composition
Recordv4, reviewed, verified Sep 30, 2026

What does the evidence say about Tesofensine?

Evidence: Human RCT evidenceGrade assigned per the methodology.

One well conducted phase 2 randomized controlled trial in obesity (Astrup 2008, n = 203, 24 weeks) showed mean weight loss of 6.7 kg (0.25 mg), 11.3 kg (0.5 mg), and 12.8 kg (1.0 mg) versus 2.2 kg with placebo and diet, equal to placebo adjusted losses of 4.5%, 9.2%, and 10.6%. Dry mouth, nausea, constipation, insomnia, and a heart rate increase of about 7 beats per minute at the top dose were seen, with blood pressure rises at 1.0 mg. No completed US phase 3 program has been published in the indexed literature.

Indexed studies by evidence grade
Evidence typeIndexed studiesParticipants (human)
Human randomized trials2203
Human observational studies0n/a
Animal studies0n/a
All indexed studies2203

Human evidence

Astrup 2008 (Lancet): 203 obese adults (BMI 30 to 40) randomized to placebo or tesofensine 0.25, 0.5, or 1.0 mg daily with a hypocaloric diet for 24 weeks. Weight loss was 2.2 kg, 6.7 kg, 11.3 kg, and 12.8 kg respectively; the 0.5 mg dose achieved most of the benefit with fewer cardiovascular effects. Adverse events were dry mouth, nausea, constipation, hard stools, diarrhea, and insomnia; heart rate rose by 7.4 beats per minute at 1.0 mg and blood pressure increased at that dose. Earlier trials in Parkinson and Alzheimer disease found no meaningful benefit for those conditions but recorded weight loss as a side effect. Doggrell 2009 reviews the trial and the cardiovascular concerns that shaped later development.

Animal evidence

Rodent studies showed reduced food intake and body weight through monoamine reuptake inhibition, consistent with the human findings. Animal data are supportive rather than the primary evidence base.

Key studies

Indexed studies of Tesofensine
StudyDesign and populationOutcomeGrade
Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial2008 PMID 18950853Randomized, double blind, placebo controlled phase 2 trial, 24 weeksn = 203 Obese adults (BMI 30 to 40) on a hypocaloric dietWeight loss 6.7 kg (0.25 mg), 11.3 kg (0.5 mg), 12.8 kg (1.0 mg) versus 2.2 kg placebo; dose related heart rate and blood pressure increasesEvidence: Human RCT evidence
Tesofensine, a novel potent weight loss medicine. Evaluation of Astrup A et al. Lancet 20082009 PMID 19548858Expert evaluation of the phase 2 trialObese adults from the 2008 trialConfirms roughly twice the weight loss of existing oral agents and highlights cardiovascular safety questions for phase 3Evidence: Human RCT evidence

Conditions studied

Conditions with evidence for Tesofensine
ConditionGradeNote
Obesity and chronic weight managementNot gradedGLP-1 based peptides are the only peptides with large randomized trials for weight loss. Semaglutide 2.4 mg produced 14.9% mean weight loss over 68 weeks and tirzepatide 15 mg produced 20.9% over 72 weeks. Retatrutide, cagrilintide, and survodutide are in late stage trials.
Fat loss and body compositionEvidence: Human RCT evidencePhase 2 weight loss of 6.7 to 12.8 kg versus 2.2 kg on placebo over 24 weeks, with dose related heart rate and blood pressure increases; a small molecule, not approved.

Is Tesofensine legal in the United States?

Regulatory: UnscheduledWADA: WADA prohibited

FDA and compounding status

Not FDA approved and not on any FDA compounding list as of the pages current to April 2026. It is a synthetic small molecule with no US marketing authorization and no 503A nomination, so there is no federal basis for a US compounding pharmacy to compound it. Some products sold online as tesofensine are unverified imports or research chemicals.

WADA status

WADA prohibited. Athletes subject to anti-doping testing should treat this as prohibited at all times unless the current prohibited list says otherwise.

Regulatory timeline

No regulatory events recorded.

Full tracker for Tesofensine or the category-wide tracker.

Email me when Tesofensine's status changes

Email only. Alerts have not started yet; we will ask you to confirm before the first one. Unsubscribe any time.

What published studies of Tesofensine used

Ranges below are reported from published studies and labeling only. PeptideAgent does not recommend doses or protocols.

Phase 2 trial doses: 0.25 mg, 0.5 mg, or 1.0 mg orally once daily for 24 weeks (Astrup 2008). The 0.5 mg dose was identified as the best balance of efficacy and tolerability. These are trial doses for an unapproved drug, not a recommendation.

Routes reported

Routes of administration reported for Tesofensine
#Route
1Oral tablet or capsule, once daily

What are the side effects and interactions of Tesofensine?

Side effects

Side effects reported for Tesofensine
#Reported side effect
1Dry mouth (most common)
2Nausea, constipation, and hard stools
3Insomnia and mood changes
4Increased heart rate (about 7 beats per minute at 1.0 mg)
5Increased blood pressure at the 1.0 mg dose
6Dizziness and headache
7Long term cardiovascular safety not established

Interactions

Interactions reported for Tesofensine
#Interaction
1Monoamine oxidase inhibitors and serotonergic antidepressants: theoretical risk of serotonin syndrome and hypertensive effects
2Stimulants and sympathomimetics: additive heart rate and blood pressure effects
3Antihypertensives: may need adjustment because of pressor effects
4No formal human drug interaction studies published

Contraindications

Contraindications for Tesofensine
#Contraindication
1Uncontrolled hypertension or cardiovascular disease
2Concurrent MAO inhibitor use
3Pregnancy and breastfeeding (no data)
4History of psychiatric illness or substance use disorder (dopaminergic drug, limited data)

How do people access Tesofensine legally?

Typical cost: Not available through licensed US channels. Products sold as research chemicals for human use are unapproved drugs and are not verified for identity or purity.

Access options

  • Not available

    No lawful United States access path identified on the last verified date outside a registered clinical trial.

  • Not available

    Not available as an FDA approved product and not eligible for compounding under section 503A or 503B.

  • Not available

    Products labeled research use only are unapproved drugs when sold for human use and are not verified for identity or purity.

Access paths are checked against public regulatory records. Products labeled research use only are never listed.

Compare Tesofensine

What's actually offered, and what that means for you

FDA has found an ingredient distributor offering tesofensine anyway. [7]

Being offered does not change the legal status of tesofensine. Tesofensine is not FDA approved and not on the 503A bulks list, so a pharmacy has no federal basis to compound it. [3] [4]

What FDA found

  • December 2025: FDA named tesofensine among the ingredients a bulk distributor supplied to 503A compounders, and said these ingredients are not eligible for human drug compounding. [7]

Enforcement is uneven. FDA mostly acts through warning letters to compounders and online sellers, Category 2 safety listings, and import alerts that let it detain shipments, rather than stopping every pharmacy. State pharmacy boards oversee pharmacies day to day, and their rules differ. [4] [8] [9] [10] [11] [12]

What that means for you

  • A pharmacy that compounds tesofensine is taking a regulatory risk: it has no federal basis to do so, and FDA has sent warning letters to compounders for the same thing. [8] [9]
  • No FDA oversight of the specific product: FDA does not check a compounded drug's safety, effectiveness, or quality before it is sold. [12]
  • State boards can act. On August 19, 2026, Mississippi's medical, nursing, and pharmacy boards said no licensed provider may prescribe, recommend, supply, or administer a peptide that is not FDA approved, and that a consent form does not remove the provider's liability. [13]
  • Louisiana acted by statute: Act 374, in effect August 1, 2026, bars its licensing boards from prohibiting peptides only when they come from a pharmacy or outsourcing facility that complies with federal compounding law. It does not make any peptide eligible to compound. [14] [15]
  • Identity, purity, sterility, and dose accuracy can vary from batch to batch. [4]
  • Insurance rarely covers it, so you usually pay cash.
  • For tested athletes, tesofensine is prohibited under the WADA Prohibited List, whatever the source. Some entries apply only in competition or only to male athletes, so check the section that covers it. [5]

If you're going ahead anyway

These steps lower some risks. They do not make the product safe, and they do not give a pharmacy a federal basis to compound tesofensine, with or without a prescription. [3]

Check the pharmacy's license. Look the pharmacy up yourself on your state board of pharmacy's license search; FDA's BeSafeRx page links every state's. If the pharmacy is not listed, or is not licensed in your state, do not use it. [16] [17] [18]

What a legitimate prescription and consult look like. Federal law lets a pharmacy compound only for an identified patient on a valid prescription. A legitimate prescriber is licensed in the state where you are, evaluates you, and tells you the drug is compounded and not FDA approved, and a telehealth company should say which pharmacy compounds it. A seller that needs no prescription, or a pharmacy with no pharmacist to answer questions, is a warning sign. [18] [19] [20]

Why this is safer than a research-use-only product. A state-licensed pharmacy answers to its state board and has a pharmacist you can reach. A product labeled "research use only" or "not for human consumption" has neither, and FDA treats such products sold for people as unapproved drugs. In a 2024 study of semaglutide sold online without a prescription, half of six orders never arrived, and every vial that did was rated probably substandard or falsified, held more drug than its label said, and contained endotoxin. Black-market growth peptides have also contained modified molecules the label did not name. Safer is not safe: compounded drugs can also be contaminated or have too much or too little active ingredient. [12] [21] [22] [23] [24] [25]

Check for:

  • A 503A pharmacy licensed in your state (your state board of pharmacy publishes license lookups). [12]
  • A real evaluation by a licensed prescriber, not just an online form.
  • A certificate of analysis for the specific batch.

Questions to ask

  • Pharmacy: What is your license number, and are you licensed in my state? Then check it yourself on the state board's site. [16]
  • Telehealth company: Which pharmacy compounds and ships this, and is it a 503A pharmacy or a 503B outsourcing facility? [20]
  • Pharmacy: Is this made for me on a prescription written in my name? [19]
  • Prescriber: Are you licensed where I am, and will you evaluate me yourself rather than rely on a questionnaire? [18] [20]
  • Prescriber: What is the legal basis for a pharmacy to compound tesofensine? Is it FDA approved or on the 503A bulks list? [3] [12]
  • Anyone offering it: Does anyone call it "FDA approved", "generic", or from an "FDA-approved pharmacy"? None of these is true of a compounded drug, so the claim is a red flag. [20]

In Mississippi, there is no legitimate prescriber route for a peptide that is not FDA approved: licensed providers may not prescribe or supply one, and a patient who gets one on their own carries the risk alone. [13]

Frequently asked questions

Is tesofensine legal in the United States?

It is not FDA approved and is not on any FDA compounding list, so no US pharmacy can lawfully dispense it. Products sold online are unapproved drugs of unverified origin. PeptideAgent has not verified approval status in any other country. [3] [4]

Does tesofensine work for weight loss?

In the one published phase 2 randomized trial, yes: 203 obese adults lost a mean 11.3 kg on 0.5 mg and 12.8 kg on 1.0 mg over 24 weeks versus 2.2 kg on placebo, about 9 to 11% placebo adjusted. That is roughly double the effect of older oral anti-obesity drugs and in the range of semaglutide at 6 months, but it comes from a single 24 week study without a published phase 3 confirmation or long term safety data. [1] [2]

What are the side effects of tesofensine?

Dry mouth, nausea, constipation, insomnia, and dizziness were the common effects in the phase 2 trial. The important concern is cardiovascular: heart rate rose by about 7 beats per minute and blood pressure increased at the 1.0 mg dose, which is why the 0.5 mg dose was favored. Long term safety has not been established. [1]

How is tesofensine taken?

As a once daily oral tablet or capsule. The phase 2 trial tested 0.25, 0.5, and 1.0 mg daily for 24 weeks alongside a reduced calorie diet. These are trial doses for a drug that has not been approved in the US. [1]

How much does tesofensine cost?

There is no licensed US price. Products sold as research chemicals for human use are unapproved drugs and are not verified for identity or purity. [4] [6]

Is tesofensine banned by WADA?

Yes. Tesofensine is named among the stimulants in section S6 of the WADA Prohibited List. Stimulants are prohibited in competition, not at all times, so check the rules of your sport and ask your anti-doping organization before any use. [5]

Is tesofensine a peptide?

No. It is a small organic molecule (a phenyltropane derivative) taken by mouth. It appears on peptide vendor sites and in peptide clinic menus because it is marketed to the same weight loss customers, not because of its chemistry. [1]

Tesofensine vs semaglutide: which is better for weight loss?

Semaglutide has far stronger evidence: about 15% average weight loss at 68 weeks in a 1,961 person trial, proven cardiovascular benefit, and FDA approval. Tesofensine's 9 to 11% placebo adjusted loss comes from one 24 week study of 203 people with unresolved cardiovascular questions and no US approval. The comparison is between a proven, available drug and an unproven, unavailable one. [1] [2]

Decisions about starting, stopping, or combining any treatment belong with a licensed clinician who knows your history.

From the blog

Sources

Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.

  1. [1]Astrup A et al. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet 2008PubMed 18950853, 2008
  2. [2]Doggrell SA. Tesofensine, a novel potent weight loss medicine. Expert Opin Investig Drugs 2009PubMed 19548858, 2009
  3. [3]FDA: Bulk drug substances used in compounding under section 503A of the FD&C ActFDA, 2026
  4. [4]FDA: Certain bulk drug substances for use in compounding may present significant safety risks (Category 2 list, content current as of April 22, 2026)FDA, 2026
  5. [5]WADA Prohibited List (sections S0 non-approved substances and S6 stimulants)WADA, 2026
  6. [6]FDA warning letter 735063, August 24, 2026, to an online seller of research-use-only peptides: products labeled research use only were unapproved new drugs (FDA warning letters database)FDA, 2026
  7. [7]FDA warning letter 716152, December 8, 2025, to a bulk drug ingredient distributor supplying compounders (FDA warning letters database)FDA, 2025
  8. [8]FDA: Compounding inspections, recalls, and other actions (warning letters to compounders)FDA
  9. [9]FDA warning letter 579286, July 30, 2019, to a state-licensed 503A compounding pharmacy (FDA warning letters database)FDA, 2019
  10. [10]FDA warning letter 735063, August 24, 2026, to an online seller of research-use-only peptides (FDA warning letters database)FDA, 2026

Cite this page

Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.

APA style
PeptideAgent. (2026, September 30). Tesofensine: evidence, legality, and access. https://peptideagent.ai/peptides/tesofensine
HTML link
<a href="https://peptideagent.ai/peptides/tesofensine">Tesofensine: evidence, legality, and access</a>, PeptideAgent, updated September 30, 2026.